List of Excipients in API remibrutinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing remibrutinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | CELLULOSE, MICROCRYSTALLINE | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | COPOVIDONE K25-31 | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | CROSCARMELLOSE SODIUM | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | FERRIC OXIDE RED | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | FERRIC OXIDE YELLOW | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | MANNITOL | 2030-09-30 |
| Novartis Pharmaceuticals Corporation | RHAPSIDO | remibrutinib | 0078-1483 | POLYETHYLENE GLYCOL 4000 | 2030-09-30 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for remibrutinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
remibrutinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
remibrutinib drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
remibrutinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
remibrutinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
remibrutinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
remibrutinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
remibrutinib drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
remibrutinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
remibrutinib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
remibrutinib drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
remibrutinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
remibrutinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | remibrutinib | 0078-1483 |
| >Company | >Ingredient | >NDC |
remibrutinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch